Instead, the pretreatment Gustave Roussy Immune (GRIm) score, which takes into account NLR, albumin, and LDH, did not show a prognostic role in patients who received pembrolizumab in the first-line setting for advanced NSCLC patients with PDL1 ≥ 50% [32]. The gene discussed is ALB; the disease is non-small cell lung carcinoma.